home infusion — Lanton Law Blog

Home Infusion Stakeholders to be Helped by Newly Introduced Congressional Legislation

According to a press release by Senator Warner (D-VA), a newly introduced “bipartisan bill in the U.S. Senate proposes to ensure Medicare patients maintain access to home infusion therapies that require the use of an infusion pump. The Preserving Patient Access to Home Infusion Act — introduced by Sen. Mark Warner (D-VA) and Sen. Tim Scott (R-SC) — would ensure patients with serious viral and fungal infections, heart failure, immune diseases, cancer, and other conditions can receive the intravenous (IV) medications they need while at home.”

The Preserving Patient Access to Home Infusion Act can be viewed here.

Amazon Launches U.S. Pharmacy Business

Many supply chain stakeholders have been fearing whether Amazon would ever open a retail pharmacy business. There have been traces of this occurring for years from its sporadic applications of pharmacy licenses in various states, to its June 2018 $753 million acquisition of PillPak. However; no coherent plan had come into focus until now.

Lanton Law to Attend 9/14-9/18 2020 NASP Annual Meeting & Expo Virtual Experience

Ron Lanton; Principal of Lanton Law addresses the National Association of Specialty Pharmacy on emerging specialty issues.

biologics, biotechnology, healthcare, home infusion, insurance, life sciences, pharmaceuticals, pharmacyRon LantonSeptember 12, 2020pharmacy, specia

The New Concerns of a Digital Workplace

We are honored to have worked with STACK for Pharmacy on a great and timely webinar titled “The New Concerns of a Digital Workplace. COVID-19 has changed the way that we work, communicate and transfer information and finances. We discuss the early trends of what we are seeing from a transitioning marketplace.

Upcoming Webinar with STACK and Lanton Law

STACK will be teaming up with Lanton Law to do an April 22, 2020 webinar at 1:00 PM EST titled “The New Concerns of a Digital Workplace.”

Lanton Law; Your Digital Lawyer & Lobbying Team

As organizational needs evolve right now, businesses are looking for innovative ways to become efficient and manage risks.

Pharmacy Times Recaps Lanton Law's NASP Presentation on the FDA Biosimilars Action Plan

During the 2019 National Association of Specialty Pharmacy Annual Meeting and Expo, Ron Lanton III, Esq, reviewed the FDA Biosimilars Action Plan, its implications for the biosimilar marketplace, recent legislation set to influence the biosimilar pathway and drug accessibility, and the future of the biosimilar market.

Conflicting CBD Activity Calls for Increased Compliance and Business Planning

Lanton Law gave a December 2019 webinar with the American College of Apothecaries ACA on CBD. Since then we have seen two significant developments.

healthcare, home infusion, life sciences, pharmaceuticals, pharmacyRon LantonDecember 26, 2019CBD, hemp, New York, FDA

Texas v. United States (An ACA Ruling)

On December 18, 2019 the industry witnessed the U.S. Court of Appeals for the 5th Circuit issue its ruling, which found that while the individual mandate is unconstitutional, the federal district court must decide on whether the remaining portion of the ACA could remain intact.

What Will Happen to Biosimilars in the USMCA Agreement in 2020?

Back in August I started an analysis of how biosimilars will be impacted in the new United States-Mexico-Canada Agreement (USMCA). To refresh, in a follow up on a 2016 campaign promise to renegotiate the North American Free Trade Agreement (NAFTA), the Administration has been engaging Mexico and Canada in an effort to create and ratify the USMCA.

Congress, healthcare, home infusion, HealthIT, biologics, BiosimilarsRon LantonDecember 23, 2019trade, USMCA

New Draft Importation Rule Released

A new pilot program that allows states to import from Canada and allow manufacturers to voluntarily import has been announced via a draft rule through HHS and the FDA. The program would give states and nonfederal government entities the ability to import from Canada by applying to the FDA. Higher priced drugs such as biologics are not included in the draft rule.

healthcare, importation, home infusion, life sciences, pharmaceuticals, pharmacy, biologicsRon LantonDecember 23, 2019importation, Canada

U.S. Solicitor General Advocates for writ of certiorari to be granted in Rutledge v. PCMA

One case that pharmacy stakeholders have been closely monitoring is Rutledge v. Pharmaceutical Care Management Association.

Not knowing what’s in your contracts can stop your business expansion

No matter if you are a hospital, physician, pharmacist, manufacturer, SAAS or Health IT provider, the lifeblood of your business is in your contracts. As an attorney what amazes me time after time is how contracts are often overlooked by businesses.

healthcare, HealthIT, home infusion, life sciences, pharmaceuticals, pharmacy, technologyRon LantonDecember 15, 2019contracts

Lanton Law Quoted in New Medscape Article On Biosimilar Insulin

A new US Food and Drug Administration (FDA) policy may help get novel biosimilar insulins to market more quickly, but it will be no guarantee that the products will be significantly less expensive than branded insulins, say analysts.

healthcare, CMS, life sciences, pharmaceuticals, pharmacy, home infusionRon LantonDecember 11, 2019insulin, FDA, Congress, insurance, biosimilars, biologics

CMS Star Ratings: Will Biosimilars Benefit?

The Centers for Medicare and Medicaid Services (CMS) star ratings system was created in 2007 for insurance plans operating under both the Medicare Advantage and Part D. This 1 to 5 system (with 5 being the highest rating) is a way for CMS to measure the value of a plan and determine whether to continue to allow it to be part of the program. However, it’s more than just the plan, since the plan’s providers play a key role in how CMS evaluates each plan.

Congress, CMS, healthcare, home infusion, life sciences, pharmacy, pharmaceuticalsRon LantonDecember 5, 2019CMS, Star Ratings, Congress

Lanton Law December 2019 Newsletter Now Available

We are out with our December 2019 newsletter. This edition covers data oversight, a Medicaid white paper and upcoming webinars.

healthcare, home infusion, life sciences, pharmaceuticals, pharmacy, technologyRon LantonDecember 2, 2019newsletter

Lanton Law's Webinar With WellSky Now Available

Our recently recorded webinar with WellSky is now available.

healthcare, home infusion, life sciences, pharmaceuticals, pharmacyRon LantonNovember 25, 2019biosimilars, home health, home infusion

The Challenges to Launching Biosimilars

Check out Ron Lanton’s interview with Specialty Pharmacy Times on “The Challenges to Launching Biosimilars” https://www.pharmacytimes.com/news/challenges-to-launching-biosimilars

healthcare, life sciences, pharmacy, home infusionRon LantonOctober 24, 2019biosimilars, biologics